Vitamin D in prostate cancer.
- Author:
Donald L TRUMP
1
;
Jeanny B ARAGON-CHING
1
Author Information
- Publication Type:Review
- Keywords: CYP24A1; androgens; inflammation; prostate cancer; vitamin D analogs
- MeSH: Antineoplastic Combined Chemotherapy Protocols/therapeutic use*; Calcifediol/blood*; Calcitriol/therapeutic use*; Clinical Trials as Topic; Ergocalciferols/therapeutic use*; Humans; Male; Prostatic Neoplasms/prevention & control*; Signal Transduction; Vitamin D/metabolism*; Vitamin D Deficiency/epidemiology*
- From: Asian Journal of Andrology 2018;20(3):244-252
- CountryChina
- Language:English
- Abstract: Signaling through the vitamin D receptor has been shown to be biologically active and important in a number of preclinical studies in prostate and other cancers. Epidemiologic data also indicate that vitamin D signaling may be important in the cause and prognosis of prostate and other cancers. These data indicate that perturbation of vitamin D signaling may be a target for the prevention and treatment of prostate cancer. Large studies of vitamin D supplementation will be required to determine whether these observations can be translated into prevention strategies. This paper reviews the available data in the use of vitamin D compounds in the treatment of prostate cancer. Clinical data are limited which support the use of vitamin D compounds in the management of men with prostate cancer. However, clinical trials guided by existing preclinical data are limited.
